Hemangiosarcoma (HSA) is an aggressive cancer in dogs and carries a poor prognosis. There are limited therapeutic options for the treatment of HSA, with none currently providing a significant opportunity for long-term survival.
The Intestinal Dysbiosis Program is investigating the associations between the presence of dysbiosis and the development and metastasis of HSA.
- Dogs with Osteosarcoma (OSA) confirmed o biopsy (with or without evidence of metastasis).
- Patients with suspected OSA based on x-rays are also eligible for enrollment, although they will be removed from the study if biopsy results are not consistent with OSA.
The study will also be enrolling health dogs that do not have OSA. These dogs must meet the following criteria:
- Up to 7 years of age.
- Weighing over 20kg.
- Apparently healthy and are not on any medications.